ShanXi C&Y Pharmaceutical Group Co.,LTD. (300254.SZ)
- Previous Close
8.51 - Open
8.26 - Bid 8.71 x --
- Ask 8.72 x --
- Day's Range
8.30 - 8.98 - 52 Week Range
4.98 - 11.60 - Volume
13,538,620 - Avg. Volume
13,593,767 - Market Cap (intraday)
2.109B - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
45.95 - EPS (TTM)
0.19 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Jul 11, 2019
- 1y Target Est
--
ShanXi C&Y Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of medicine and health food products. It offers anti-infective drugs, anti-allergic drugs, respiratory system drugs, urinary system drugs, kidney disease drugs, children's drugs, cardiovascular and cerebrovascular drugs, antidepressants, medicines, pharmaceutical raw materials, and intermediates, etc. The company's product portfolio includes Fosfomycin tromethamine powder, Mezlocillin sodium sulbactam sodium for injection, Ebastine tablets, Tamsulosin hydrochloride sustained release capsules, Cinacalcet hydrochloride tablets, Apixaban tablets, Rivaroxaban tablets, Flouxetine hydrochloride capsules, Ambroxol hydrochloride dispersible tablets, Smectite powder, Vitamin AD drops, and Baoling Yunbao oral liquid, as well as provides DNA gene preservation services. It also provides medical and health services and commercial services, such as medical diagnosis, gene preservation, and pregnancy environment testing services. The company was formerly known as Shanxi C&Y Pharmaceutical Co., Ltd. and changed its name to Shanxi C&Y Pharmaceutical Group Co., Ltd. in September 2014. Shanxi C&Y Pharmaceutical Group Co., LTD. was founded in 2005 and is headquartered in Datong, China.
www.cy-pharm.com1,234
Full Time Employees
December 31
Fiscal Year Ends
Sector
Related News
Performance Overview: 300254.SZ
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300254.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300254.SZ
Valuation Measures
Market Cap
2.11B
Enterprise Value
2.39B
Trailing P/E
46.21
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.62
Price/Book (mrq)
3.41
Enterprise Value/Revenue
2.97
Enterprise Value/EBITDA
23.43
Financial Highlights
Profitability and Income Statement
Profit Margin
5.66%
Return on Assets (ttm)
1.51%
Return on Equity (ttm)
9.20%
Revenue (ttm)
805.61M
Net Income Avi to Common (ttm)
45.64M
Diluted EPS (ttm)
0.19
Balance Sheet and Cash Flow
Total Cash (mrq)
131.92M
Total Debt/Equity (mrq)
30.90%
Levered Free Cash Flow (ttm)
-314.17M
Company Insights: 300254.SZ
300254.SZ does not have Company Insights